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Abstract
Background: Anderson’s disease (AD) or chylomicron retention disease (CMRD) is a very rare hereditary lipid
malabsorption syndrome. In order to discover novel mutations in the SAR1B gene and to evaluate the expression,
as compared to healthy subjects, of the Sar1 gene and protein paralogues in the intestine, we investigated three
previously undescribed individuals with the disease.
Methods: The SAR1B, SAR1A and PCSK9 genes were sequenced. The expression of the SAR1B and SAR1A genes in
intestinal biopsies of both normal individuals and patients was measured by RTqPCR. Immunohistochemistry using
antibodies to recombinant Sar1 protein was used to evaluate the expression and localization of the Sar1
paralogues in the duodenal biopsies.
Results: Two patients had a novel SAR1B mutation (p.Asp48ThrfsX17). The third patient, who had a previously
described SAR1B mutation (p.Leu28ArgfsX7), also had a p.Leu21dup variant of the PCSK9 gene. The expression of
the SAR1B gene in duodenal biopsies from an AD/CMRD patient was significantly decreased whereas the
expression of the SAR1A gene was significantly increased, as compared to healthy individuals. The Sar1 proteins
were present in decreased amounts in enterocytes in duodenal biopsies from the patients as compared to those
from healthy subjects.
Conclusions: Although the proteins encoded by the SAR1A and SAR1B genes are 90% identical, the increased
expression of the SAR1A gene in AD/CMRD does not appear to compensate for the lack of the SAR1B protein. The
PCSK9 variant, although reported to be associated with low levels of cholesterol, does not appear to exert any
additional effect in this patient. The results provide further insight into the tissue-specific nature of AD/CMRD.
Background
Anderson’ disease (AD) (OMIM 246700) or Chylomi-
cron Retention Disease (CMRD) are the terms used to
describe a disorder characterized by hypobetalipoprotei-
nemia with selective absence of apoB48 in the post
prandial state [1-26]. It is a very rare recessively inher-
ited disease with less than 50 cases having been reported
in the literature. Subjects with this disorder exhibit the
clinical manifestations initially described by Anderson
and her colleagues which consist of a malabsorption
syndrome with steatorrhea and failure to thrive [1].
Endoscopy shows a typical white stippling, like hoar
frosting, covering the mucosal surface of the small intes-
tine. The enterocytes in intestinal biopsies contain accu-
mulations of large lipid droplets free in the cytoplasm as
well as membrane-bound lipoprotein-sized structures
[2,8,10-14,17]. Neuro-retinal manifestations are occa-
sionally present in young patients [8,10,11,19,24]. How-
ever, neurological signs may develop more frequently
later in untreated individuals and consist most fre-
quently of the loss of deep tendon reflexes [8,10,19,24].
When diagnosis and treatment do not occur until
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and myopathy, may be more severe [4,5,21]. Recently,
myolysis was reported in 8 patients with AD [21]. In all
the patients reported in the literature, there is an
absence of apoB48-containing lipoproteins. ApoB100-
containing lipoproteins are present, although frequently
in decreased amounts. There are low levels of plasma
high density lipoprotein (HDL)-cholesterol, total lipids,
cholesterol, phospholipids, carotenoids and lipid soluble
vitamins (particularly vitamin E) whereas fasting trigly-
ceride levels are in the low normal range. Plasma
apoB100 and apoAI levels are 20-70% of normal.
Increased amounts of apoB48, apoAI and apoAIV have
been found in enterocytes [5,6,8]. Acanthocytosis is
exceptional and there have been no reports of retinitis
pigmentosa. A low fat diet supplemented with lipid
soluble vitamins (A and E) results in the resumption of
normal growth with abatement of the gastrointestinal
symptoms.
In several patients (Table as Additional file 1), the
molecular basis for the defect in chylomicron secretion
has been shown to be a mutation in the SAR1B
(formerlyS A R A 2 )gene which encodes the SAR1B pro-
tein [18-24,26]. This protein belongs to the Sar1-ADP-
ribosylation factor family of small GTPases and it is
involved in the vesicular coat protein complex II
(COPII)-dependent transport of proteins from the endo-
plasmic reticulum to the Golgi apparatus [27-30].
Recent studies of chylomicron assembly have shown
that the Sar1/COPII protein complex also is required
for fusion of the specific chylomicron transport vesicle,
the PCTV (pre-chylomicron transport vesicle), with the
Golgi [31-35]. The SAR1B gene (OMIM 607690) is
located at 5q31.1. It is composed of 8 exons and alterna-
tive splicing of exon 2 is predicted to lead to two tran-
scripts (NM_001033503, NM_016103). To date, 15
SAR1B gene mutations (frameshifts, missense or dele-
tions, Figure as Additional file 2) have been described in
patients with AD or CMRD [18-24]. A second human
protein isoform of Sar1, SAR1A, is encoded by the
SAR1A gene (OMIM 607691) which is located at
10q22.1. SAR1A also is composed of 8 exons. As in the
case of SAR1B, alternative splicing of exon 2 is predicted
to lead to two transcripts (NM_001142648, NM_020150).
To date, no mutation in the SAR1A gene has been
described in patients with AD/CMRD.
We describe here three individuals with mutations in
the SAR1B gene from two previously undescribed
families. Two children in the first family carry a novel
mutation. In the second family, one child carries a pre-
viously described mutation in the SAR1B gene and,
unexpectedly, a polymorphism in the PCSK9 gene (Pro-
protein convertase subtilisin/kexin type 9). This poly-
morphism is of interest because heterozygous variations
in the PCSK9 gene have been found, recently, to be a
major additional determinant of circulating levels of
LDL-cholesterol in humans [36-39].
Finally, for the first time, we describe the differential
expression of the SAR1A and SAR1B genes and the loca-
lization of the Sar1 proteins in the enterocytes of intest-
inal biopsies from Anderson’s disease patients as
compared to healthy individuals.
Patients and Methods
Patients
Patient AD1, a boy born in 1998, was the first of 3 chil-
dren of Turkish consanguineous first degree parents. The
plasma total cholesterol levels of the father (2.4 g/L) and
the mother (2.6 g/L) and their LDL cholesterol levels
(2.0 and 1.55 g/L, respectively) were in the normal range
for the laboratory. The patient was admitted to the uni-
versity hospital at 10 months of age with chronic diarrhea
(from the age of 3 months) as the main clinical symptom
along with moderate growth retardation (-1SD in weight)
and a distended abdomen. The neurological examination
was normal.
Patient AD2, a girl born in 2003, is AD1’ss i s t e r .S h e
was first admitted to the hospital at one month of age
for moderate growth retardation (-1SD in weight), sub-
acute diarrhea and a distended abdomen.
Patient AD3, a girl born in 1990, was the last of 8 chil-
dren from unrelated Moroccan parents. The mother’s
cholesterol level was normal. The father is no longer a
participant in the family and his lipid levels are not avail-
able. Diarrhea, which began at 3 months of age, was the
main clinical symptom. At 8 months of age, the patient
was hospitalized for growth retardation (-2 SD in weight
and -2 SD in height) and a distended abdomen.
Blood samples and intestinal biopsies were collected
from the patients and normal control subjects, using the
procedures and the experimental methods approved by
INSERM (RBM 0256) and by a bioethics committee
(Comité Consultatif de Protection des Personnes dans la
Recherche Biomédicale de Paris Bichat-Claude Bernard,
Paris, France, CCPPRB Bichat-C. Bernard-2003/05).
Informed, written consent was obtained from all partici-
pants or from their legal guardians.
Intestinal biopsies
For diagnostic purposes, duodenal biopsies were
obtained, after a 12-15 hour fast, from the patients and
from 7 healthy subjects (2 children, 4 and 8 years old,
respectively, 1 young adult, 23 years old and 4 older
adults, 54 to 64 years old) undergoing endoscopy for
causes unrelated to malabsorption and who were follow-
ing their normal diet. Duodenal biopsies either were
fixed in buffered formalin and further embedded in par-
affin for standard histology and immunohistochemistry
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staining of the lipids and for the analysis of intestinal
SAR1A and SAR1B gene and protein expression. Elec-
tron microscopy of the biopsies was performed as pre-
viously described [14].
Lipid and lipoprotein analysis
Venous blood samples were drawn after a 12-hour fast
(T0) and then 90 min. (T90) and 180 min. (T180) after
a standard lipid load. The lipid load was a 620 kcal-meal
that was given at T0 immediately after the drawing of
the fasting blood samples. It contained about 66% lipids,
with monounsaturated fatty acids present in a higher
proportion than the saturated fatty acids. Typically, it
was composed of 200 mL of unskimmed milk with
sweetener, 50 g of bread, 10 g of butter and 100 g of
cream (30% fat) with sweetener. Total cholesterol (TC)
and triglyceride concentrations were determined by
automated enzymatic methods (Konelab, Thermoclinical
Labsystems, Cergy Pontoise, France, and Biomerieux,
Marcy L’Etoile, France, respectively) [40,41]. HDL-
cholesterol (HDL-C) was determined by a direct method
according to Egloff et al. [42]. LDL-cholesterol (LDL-C)
was calculated using Friedewald’se q u a t i o n[ 4 3 ] .A p o A I
and apoB were measured by immunonephelometry
using anti-apoAI and anti-apoB antisera (Dade-Behring)
and a BN II nephelometer analyzer from Behring (Dade
Behring, Marburg GmbH, Germany) [44]. Total lipopro-
teins were isolated by ultracentrifugation (d < 1.21 g/mL
for 4 hours at 90,000 rpm in a NVT 90 Beckman rotor)
and analyzed by SDS-polyacrylamide gel electrophoresis.
Western blotting was performed with three monoclonal
antibodies (generous gift of Y. Marcel) to detect the pre-
sence of apoB48, apoB100 and possible truncated forms
of apoB [45,46]: the antibodies are specific for 1) the N-
terminal side of apoB100 and apo B48 (antibody 1D1
recognizes epitopes located between amino acids 474
and 539 of the protein), 2) for the C-terminal side of
apoB100 (antibody L3 recognizes the epitopes close to
amino acid 4355) and 3) for the central part of apoB
(antibody L9 is specific for amino acids located between
residues 2835 and 2922 present in both apoB48 and
apoB100).
Gene sequencing of SAR1A, SAR1B, PCSK9 and exon 7 of
the LDLR
Genomic DNA was isolated from whole blood contain-
ing EDTA with a PSS Magtration 8 Lx machine using a
magnetic marble technique, according to the manufac-
turer’s instructions. The 8 exons of SAR1A, the 8 exons
of SAR1B,t h e1 2e x o n so fPCSK9 and exon 7 of the
LDLR genes and their flanking intronic sequences, were
amplified by the polymerase chain reaction (primer
sequences and PCR conditions are available on request).
These genes were tested because of their known roles in
the secretory pathway and/or their involvement in hypo-
cholesterolemic syndromes. Exon 7 of the LDLR gene
encodes the EGF A repeat domain of the LDL receptor
which is essential for PCSK9 binding. Bidirectional
fluorescent sequencing of purified PCR products (Exo-
SAP-IT, GE Healthcare) was carried out with the Big
Dye
® Terminator v1.1 Cycle Sequencing kit on an ABI-
PRISM
® 3130XL genetic analyzer (Applied Biosystems,
Applera France SA). Electrophoretograms were analyzed
using Gensearch DNA sequence analysis software (Phe-
nosystems SA., Belgium).
Immunohistochemical studies of the intestinal biopsies
The localization of Sar1 proteins in duodenal biopsies
from the 3 AD patients and from 3 of the healthy sub-
jects was assessed by immunostaining with Nova Red
(VECTOR) using a chicken polyclonal antibody against
recombinant human SAR1A protein (ABCAM 14270,
dilution 1:100) and anti-chicken horseradish peroxidase-
conjugated antibody (ABCAM 6877, dilution 1:2000).
Expression of the SAR1A and SAR1B genes in the
intestine
For the analysis of gene expression, intestinal biopsies
were frozen immediately in liquid nitrogen and then
stored in liquid nitrogen or at -80°C. Total RNA was
extracted from the frozen intestinal biopsies using the
RNeasy Mini kit (Qiagen) and treated according to the
manufacturer’s recommendations. The quantity and qual-
ity of the RNA were assessed using a Nanodrop ND-1000
spectrophotometer (Thermo Fisher Scientific Inc.). The
integrity of the RNA was evaluated by agarose gel electro-
phoresis. Reverse transcription was performed using the
Superscript II Reverse Transcriptase protocol for random
hexamer-mediated cDNA synthesis (Invitrogen).
Real time quantitative PCR was performed with the ABI
Prism model 7300 Sequence Detection System (Applied
Biosystems), using the Taqman MGB specific probes for
SAR1A (Hs00833068_s1), for SAR1B (Hs01011583_m1)
(Applied Biosystems), and Absolute blue QPCR ROX mix
(Abgene). The GAPDH (Hs99999905_m1) and POLR2A
(Hs00172187_m1) genes were used as housekeeping con-
trol genes after validation (Applied Biosystems). The
assays amplified single, gene-specific amplicons of the cor-
rect sizes (without non-specific products) and with uni-
form PCR efficiencies. All probes were validated in
triplicate by the use of serial cDNA dilutions. Target and
reference amplifications exhibited 100 ± 5% efficiency
(R
2>99% for the standard curve). The range of the Ct
values was 10-35. The standard deviation for the Ct values
of each sample was less than 0.3. Each sample was ana-
lyzed in triplicate and then differences in the expression of
each gene among the samples were quantified using the
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and POLR2A (both gave similar results) [47]. The differ-
ence in expression between the AD sample and the sample
from each healthy subject was evaluated by Student’s
tt e s t .
Results
The diagnosis of Anderson’s disease in the three
patients was made on the basis of the observations
described below which, collectively, are pathognomonic
for the disease. Celiac disease, cystic fibrosis and cow’s
milk allergy were all ruled out.
Biological results and intestinal structure and
ultrastructure
In patient AD1, the total vitamin E level as well as the
ratio of vitamin E to [cholesterol + triglyceride] were
low. The vitamin A level was normal. The plasma total
cholesterol, LDL-cholesterol, HDL-cholesterol, and
apoAI values were low whereas apoB levels were low
normal and triglyceride levels were normal (Table 1).
There were a few acanthocytes (<1%). The values for
ASAT and CK were slightly increased (Table 1) and the
CPK-MB levels were normal. After a 12 - hour fast,
intestinal video-endoscopy showed the typical « white
hoary frosting » on the mucosa and duodenal biopsies
exhibited fat loaded enterocytes typical of those seen in
Anderson’s disease (shown in Figure 1b for AD2) as com-
pared to normal individuals (Figure 1a). The intestinal
biopsy exhibited normal villi. Enterocytes from AD
patients were overloaded with fat droplets in a heteroge-
neous manner (enterocytes stained positively with oil red
O mainly on one side of the villus) (compare Figure 1c,
from a normal individual, with Figure 1d, e). Ultrastruc-
tural examination of the biopsies showed that the entero-
cytes contained an accumulation of numerous free lipid
droplets as well as membrane bound lipoprotein-sized
structures that accumulated in the enterocytes (similarly
a si nF i g u r e2f o rA D 2a n dA D 3 ) .A t1 1m o n t h so fa g e ,
vitamin E supplementation (a-tocopherol 100 mg/kg/d)
and a 60% Medium Chain Triglycerides (MCT) formula
was initiated. After a few weeks, the diarrhea improved
and the steatorrhea ceased. At 4 years of age, exocrine
pancreatic insufficiency (EPI) was suspected because of a
recurrent lipid malabsorption syndrome. Between 4 and
10 years of age, several slightly decreased fecal elastase
levels (70 to 200 μg/g) were noted and steatorrhea was
documented on several occasions (maximum 7.4 g/d at
8 years of age).
Currently, despite a normal fat diet, the patient (now 11
1/2 years old) is doing well and, surprisingly, no diarrhea
has been reported. Following vitamin E (a-tocopherol
50 mg/kg/d) and exogenous pancreatic enzyme supple-
mentation, the plasma vitamin E and fecal elastase levels
have become normal and steatorrhea is absent. The total
plasma cholesterol (1 g/L), HDL-cholesterol (0.11 g/L) and
LDL-cholesterol (0.76 g/L) values, however, remain low.
The plasma CK levels are increased (2.6 fold greater than
the upper limit of normal) but the CK-MB levels are nor-
mal. There are no neuro-ophtalmic, hepatic or cardiac
abnormalities.
In patient AD2, the plasma concentration of fat-soluble
vitamin A and the ratio of vitamin E to total lipids were
decreased (Table 1). The plasma total cholesterol, LDL-
cholesterol, HDL-cholesterol, apoAI, and apoB levels were
low whereas the triglyceride level was normal (Table 1).
The values for ASAT and CK were increased whereas CK-
MB levels were normal (Table 1). Steatorrhea was present
and fecal elastase levels were low (47 μg/g) when the
patient was evaluated initially. Exogenous enzyme supple-
mentation did not modify pancreatic function. The
video-endoscopy of the intestine and the microscopic
appearance of the intestinal biopsy (staining with oil red
and electron microscopy), shown in Figures 1 and 2 along
with images for AD3, were similar to that of patient AD1.
At 2 months of age, the patient was given liposoluble vita-
mins and MCT supplementation as for AD1.
Currently, the patient (now 7 years old), like her
brother, consumes a normal fat diet supplemented with
Table 1 Clinical and biological data of Patients
Patients AD1 AD2 AD3
Parental consanguinity yes no
Age of onset of symptoms 3
months
1
month
3
months
Growth retardation
Weight -1 SD -1 SD - 2 SD
Height Normal Normal - 2 SD
Digestive symptoms diarrhea, abdominal distension
Deep tendon reflexes + + +
Hematological (Acanthocytes) < 1% Normal 5%
Steatorrhea (g/24 hr) 2.2 4.9 2
Cholesterol (N: 1.50 - 2.80) 1.01 1.05 0.89
LDL-cholesterol (N: 0.80 -
1.50)
0.57 0.49 0.38
(g/L) HDL-cholesterol (N >0.45) 0.22 0.32 0.27
Triglycerides (N: 0.50 - 1.70) 1.10 1.20 1.20
ApoA-1 (N: 1 - 2.15) 0.70 0.90 0.50
ApoB (N: 0.55 - 1.40) 0.56 0.43 0.82
Vitamin E (N: 8 - 17 mg/L) 1.8 2.8 1
Vitamin E/Lipid (N >1.9 mg/g) 0.9 1.3 0.5
Vitamin A (N: 240 - 900 mg/L) 682 107 254
ASAT (x ULN) 1.5 1.6 1
ALAT (x ULN) 1 1 1
CK (x ULN) 1.7 1.4 1.7
ULN: Upper limit of normal; SD: Standard Deviation; + present in decreasing
amounts; ASAT: Aspartate Amino Transferase; ALAT: Alanine Amino
Transferase; CK: Creatine kinase.
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as with exogenous pancreatic enzymes. She is a healthy
young girl without digestive symptoms. The values for
liposoluble vitamins and fecal elastase are in the normal
range and steatorrhea is absent. The plasma total cho-
lesterol, HDL- and LDL-cholesterol remain low (1.2,
0.18 and 0.86 g/L, respectively). The plasma CK and
ASAT levels are increased (1.2 fold and 1.4 fold greater
than the upper limit of normal, respectively) whereas
the CK-MB levels are normal. Similarly to her brother,
there are no neuro-ophtalmic, hepatic or cardiac
abnormalities.
In patient AD3, there was a very low ratio of vitamin
E to [cholesterol + triglyceride] whereas the vitamin A
level was normal (Table 1). The plasma total cholesterol,
LDL-cholesterol, HDL-cholesterol and apoAI levels were
very low, whereas triglycerides and apoB levels were
normal (Table 1). Fecal elastase level was normal. Ane-
mia (normochromic, normocytic and then microcytic)
with decreased serum iron and decreased saturation was
present. A few acanthocytes were observed (5%). The
video-endoscopy of the intestine and the microscopic
appearance of the intestinal biopsy (staining with oil red
and electron microscopy) resembled that of patient AD2
Figure 1 Intestinal endoscopy after a 12-hour fast. In contrast to what is observed in a normal subject (a), video-endoscopy of the
duodenum (D3) of patient AD2 (b), shows the typical « white hoary frosting » on the small intestinal mucosa. In contrast with a normal subject
(c), light microscopy of the duodenal biopsy from AD2 (d) shows the typical vacuolated enterocytes (black arrows) that stain positively with oil
red O (e, black arrows). Note the typical heterogeneous aspect of the villi either fat loaded (black arrows) or without lipid droplets (white arrows).
Goblet cells are normal (d, arrow g). (c ×100; d ×400; e ×200).
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vitamin supplementation (a-tocopherol 60 mg/kg/j) was
initiated at 9 months of age.
Currently, the patient (now 19 ½ years old) follows a
self-imposed low fat diet with vitamin D and E (oral toco-
fersolan 300 mg/d) supplementation but without strict
adherence. The growth curve remains below the normal
range (-1.5 SD) which, however, must be interpreted in
the context of a short familial and ethnic height (BMI
30
th percentile). The digestive symptoms now have disap-
peared. The deep tendon reflexes are present and there
are no muscular symptoms. There is no steatorrhea and
the fecal elastase level is normal. The plasma total
cholesterol, HDL-cholesterol and LDL-cholesterol levels
remain low (0.68, 0.14, 0.39 g/L respectively). The ratio
of vitamin E to total lipids and the vitamin D level
(55 μg/L) are now normal. The electromyogram shows
neither neurogenic nor myogenic abnormalities. Nerve
conduction velocity is normal. The CK levels are slightly
increased (2-fold higher than the upper limit of normal)
although CK-MB and transaminase levels are normal.
There is no hepatic steatosis (normal abdominal ultra-
sound), no cardiomyopathy (normal cardiac ultrasound)
and no ophthalmic abnormality.
Either fasting or following a fat load, the patients
exhibited lipid and apolipoprotein levels typical of those
Figure 2 Electron microscopy of duodenal biopsies of patients with AD. As shown for AD3 (a, b, c) and AD2 (d, e), two types of particles
are apparent in the enterocytes in these patients (a,d): large lipid droplets, free in the cytoplasm (L), and smaller, lipoprotein-sized like particles
(Lp), surrounded by a membrane. A higher magnification shows in (b) some individual lipoprotein-sized particles surrounded by a membrane (*)
near a Golgi apparatus (G) which appears distended but devoid of particles and in (c,e) numerous lipoprotein-sized particles accumulated in a
membrane bound compartment (membrane, white arrow). The intercellular spaces are empty. The cell nucleus is labelled N.
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[6]. In patients AD1 and AD3, there was no increase in
triglyceride levels at 90 and 180 minutes after the fat
meal as compared to the fasting value (Table 2). Typi-
cally, in normolipidemic subjects, although a fat load
produces no significant change in total cholesterol con-
centration, the triglycerides increase after a fat meal
[48]. No chylomicrons were observed following the
lipid-rich meal in patients AD1 and AD3, whereas in
healthy normolipidemic subjects chylomicrons are easily
demonstrable 90 and 180 minutes after the fat load.
SDS polyacrylamide gel electrophoresis of lipoproteins
from the patients following the fat load showed that
apoB100 was present whereas apoB48 was undetectable
at all the times studied. No truncated form of apoB was
detected at any time.
As far as can be determined from the literature, the
acquisition of tolerance to fat in the diet is limited to
only a few cases (the two reported here and [[11,12],
and [22]]). In all the other instances reported, the
patients’ gastrointestinal symptoms recur when fat is
reintroduced into the diet. Charcosset and colleagues
[19] have proposed that network(s) of modifier genes
are involved in the mechanism(s) that determine(s) the
phenotype of the disease in a given individual. Whether
this could be a mechanism that is involved in the acqui-
sition of tolerance to fat is unknown at present.
Mutations in the SAR1B and PCSK9 genes
Sequencing of all the exons of the SAR1A and SAR1B
genes, including the intron-exon boundaries revealed
that the two siblings, patients AD1 and AD2,h a da
mutation in exon 4 (formerly exon 3) of the SAR1B
gene. There is a homozygous deletion at position 142
(c.142delG) of the SAR1B gene (Figure 3a). This deletion
results in the replacement of the aspartic acid at posi-
tion 48 by a threonine and also gives rise to a frameshift
resulting in a premature stop codon 17 amino acids
further on (p.Asp48ThrfsX17). This is a novel mutation
in the SAR1B gene and gives rise to a truncated protein
that has only 32% of the length of the normal protein
and comprises only 24% of the normal sequence.
Patient AD3 has a homozygous two base pair deletion
(c.83_84delTG) in exon 4 (formerly exon 3) of the SAR1B
gene (Figure 3b). This deletion substitutes an arginine for
the leucine normally present at position 28. A frameshift,
resulting in a premature stop codon (p.Leu28ArgfsX7),
produces a truncated protein that has only 17% of the
length of the normal protein and 14% of the normal
sequence. This mutation has been reported previously in
patients of European and Moroccan origin [18,23] (Table
as Additional file 1). Because of their different ethnic ori-
gins, it is very unlikely that the mutational event reported
here and in Cefalu et al. in patients from North Africa are
the same as the one described by Jones et al.
The PCSK9 gene was also sequenced in these patients
because it has been found to be a determinant in the
levels of circulating LDL-cholesterol. In patient AD3,
there was also a hypocholesterolemic variant in the
PCSK9 gene. AD3 is a heterozygous carrier of a 3-base
duplication (c.61_63dupCTG formerly designated
c.43_44insCTG) in the first exon of PCSK9 (Figure 3c).
The predicted amino acid change is a leucine duplica-
tion (p.Leu21dup formerly designated p.L15_16insL) in
the leucine stretch of the PCSK9 signal peptide which
leads to 10 leucine repeats (allele denoted L10) instead
of the nine leucine repeats (L9) in the normal allele.
This PCSK9 hypocholesterolemic variant has been
reported previously [49]. There was no mutation in the
12 exons or intron-exon boundaries of PCSK9 in
patients AD1 and AD2.
Finally no mutation in the SAR1A gene or in exon 7
of the LDLR gene was detected in any of the three
patients.
Table 2 Plasma lipid, apolipoprotein, and lipoprotein analysis in two AD subjects after a fat load*
Patients AD1 AD3 Fasting normal range After a fat load,
T90-T180
T0 T90 T180 T0 T90 T180
Total cholesterol 1.06 1.03 1.09 0.90 0.91 0.94 1.20-2.20 No change
LDL-cholesterol 0.73 0.70 0.76 0.56 0.56 0.62 0.40-1.10
HDL-cholesterol 0.21 0.22 0.21 0.19 0.20 0.19 0.40-0.65
Triglycerides 0.58 0.57 0.58 0.74 0.74 0.66 0.35-1.30 1.68-2.04
ApoA-I 0.71 0.68 0.67 0.65 0.63 0.59 1.30-1.80
ApoB 0.68 0.65 0.65 0.57 0.58 0.53 0.50-1.00
Chylomicrons in serum Absent Absent Absent Absent Absent Absent Absent Present
Presence of apoB48 in isolated lipoproteins No No No No No No No Yes
Presence of apoB100 in isolated lipoproteins Yes Yes Yes Yes Yes Yes Yes Yes
*Values are given in g/L.
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from normal individuals and AD patients
In the healthy subjects, the Sar1 proteins were detected
readily in the duodenal epithelium. The immunostaining,
present mainly in the upper two-thirds of the villi,w a s
localized essentially within the apical area of the cytoplasm
of the enterocytes underlying the brush border (Figure 4a).
The distribution of the Sar1 proteins was heterogeneous
along the villi with staining present predominantly on one
side of the villus. All the control reactions were negative
and no immunostaining was detected in the brush border
or in the goblet cells (Figure 4d).
In the 3 patients with Anderson’s disease, the entero-
cytes were distended by large accumulated lipid droplets.
Figure 3 Mutations in the SAR1B and PCSK9 genes. Electropherograms show (a) the c.142delG mutation in the SAR1B gene of patients AD1
and AD2, (b) the c.83_84delTG mutation in the SAR1B gene of patient AD3 and (c) the c.61_63dupCTG polymorphism in the PCSK9 gene of
patient AD3.
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Page 8 of 16As in the case of healthy individuals, the immunostaining
for the Sar1 proteins was heterogeneously distributed
along the villi. However, the staining was decreased as
compared to the healthy subjects and was restricted to
the area surrounding the lipid droplets (Figure 4b, c).
T h eS a r 1i s o f o r m sd i f f e rb yo n l y2 0a m i n oa c i dr e s i d u e s ,
which occur throughout the entire sequence of the pro-
tein, and the polyclonal antibodies used do not discrimi-
nate between the two human protein isoforms, Sar1a and
Sar1b. Therefore, we decided to analyse the expression of
the SAR1A and SAR1B genes in the intestinal biopsies.
Expression of the SAR1A and SAR1B genes in duodenal
biopsies
Real time quantitative PCR (Figure 5) showed that the
expression of SAR1B was significantly (p < 0.01)
decreased (between 1.4 and 3.5 fold) in the duodenal
biopsies of the Anderson’s disease patient AD3, as
Figure 4 Distribution of Sar1 proteins in duodenal biopsies from healthy individuals and AD patients. Immunostaining for Sar1 proteins
in normal control subjects (a) was detected mainly in the villus tip (black arrows) in the apical part of the enterocytes. The villi exhibit a
heterogeneous aspect: immunolabelling occurs predominantly on one side (black arrows) and is largely absent on the other side (empty arrows).
In patients with AD, AD2 (b) and AD3 (c), the immunolabelling for Sar1 was present in the same area of the villi but was clearly decreased in
intensity as compared to normal individuals. The immunostaining was detected around the large lipid droplets which distended the cytoplasm
of the enterocytes. The same heterogeneous aspect observed in the normal individuals was also seen in the AD subject with staining appearing
as slightly positive on one side (black arrows) and negative on the other side (empty arrows). No staining was seen when the primary antibody
was omitted (d). (Fig. a ×20; b, c, d, × 10; insert × 40).
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Page 9 of 16compared to biopsies of 4 healthy adults (aged 54 to 64
years old), a young adult (23 years old) obtained on two
separate occasions and 2 children (4 and 8 years old)
one of which was obtained on two separate occasions.
In contrast, the level of expression of SAR1A was signifi-
cantly (p < 0.01) increased (between 1.4 and 2.7 fold) in
the biopsies of the Anderson’s disease patient as com-
pared to biopsies of the same healthy individuals, except
for individual NA1 (Figure 5). Biopsies that were taken
on two separate occasions from the young adult, YA1,
and one of the children, C1, gave similar results. The
UniGene EST profile database which provides estimates
of mRNA abundances indicates that SAR1B is expressed
between 2.5 and 3 times the level of SAR1A in the intes-
tine. Our results show that, in AD/CMRD, the level of
SAR1B decreases by almost two thirds whereas SAR1A
increases by about 1.5 fold. Thus, although SAR1A
increases, this is not enough to compensate for the
decrease in SAR1B and the total amount of SAR1 pro-
teins in the intestine is predicted to be less, by about
one third, in AD/CMRD patients as compared to nor-
mal individuals. These results are, thus, in agreement
with the immuno-histochemistry results.
Discussion
In addition to manifesting the clinical, biochemical and
intestinal ultrastructural features typical of AD, includ-
ing mutations in the SAR1B gene, the 3 new patients
that we describe here (which have now been followed
for 7-10 years) exhibit some heretofore unseen features.
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Page 10 of 16The expression of SAR1B in sites other than the intes-
tine [18,50,51] suggests that other clinical manifestations
might occur in AD patients, such as the recently reported
muscular and cardiac manifestations [21]. As in several
other cases of AD/CMRD [1-3,7,10,12-14,21,23], AD3
manifests anemia and decreased levels of serum iron.
Although the mechanism is not entirely clear, these
observations are of interest in light of a report of the pre-
ferential expression of SAR1B during erythropoiesis [52]
and considering that mutations in SEC23B, with which
SAR1 interacts in the COPII secretory coat complex,
cause congenital dyserythropoietic anemia type II [53].
Further, two of our patients manifest slight acanthocyto-
sis as do four other cases reported in the literature
[5,8,10,13] and two other instances not published. In abe-
talipoproteinemia (ABL, MIM 200100), acanthocytosis
(generally more than 50% [54]) has been proposed to be
due to changes in the fluidity of the red blood cell mem-
brane as a consequence of changes in its composition
(decreased cholesterol and phospholipids leading to a
relative increase in sphingomyelin [55]). The origin of the
slight acanthocytosis (always less than 5%) in AD/CMRD
is not clear. There is only one investigation of red blood
cell lipids in AD/CMRD patients [9] and it showed that
although total cholesterol and phospholipids were
decreased, there was no variation in the phospholipid
composition and the phosphatidylcholine to sphingomye-
lin ratio was similar to that in normal subjects (but no
acanthocytosis was reported in those patients). Other fac-
tors may be involved. Normal erythrocytes acquire an
acanthocytic form after transfusion into and circulation
in ABL patients [56] but incubation of normal erythro-
cytes with plasma from ABL patients does not result in
these modifications [57,58]. This suggests that the
mechanism(s) of formation of the acanthocytes in ABL
are complex and do not simply result from the passive
exchange of lipids between the erythrocyte membrane
and the plasma but also may reflect exchange with the
vessel wall membranes. There are no acanthocytes in the
bone marrow of AD3 [59] which also suggests a periph-
eral acquisition in AD/CMRD. The decreases in choles-
terol and phospholipids in AD/CMRD may be at the
limit at which changes in membrane fluidity induce
changes in erythrocyte morphology thus making the find-
ing of acanthocytes inconstant and variable in the
disorder.
Osteoporosis/osteopenia have been described in several
cases of AD [1-3,10,11,14,24] although none of the 3
cases reported here exhibit such abnormalities. In these 3
new patients, except for slightly increased CK levels,
there is no neuro-ophtalmic, hepatic or cardiac abnorm-
ality. Further, none of the patients have any abnormal
clinical or biological signs related to the spleen, kidney or
lungs. The retardation in growth, which is milder than
previously reported for patients with AD, underscores
once more the importance of an early diagnosis which
permits the implementation, early in life, of a low fat diet
supplemented with liposoluble vitamins.
In both AD1 and AD2, exocrine pancreatic insufficiency
(EPI) was suspected because of low fecal elastase levels.
Whether and to what extent SAR1B gene mutations [60]
can affect the levels of fecal elastase is unknown. Even
though the low fecal elastase levels in AD1 and AD2 (AD3
had a normal fecal elastase level) could be due to diarrhea-
related dilution and there are no other indications of pan-
creatic dysfunction, investigation of pancreatic function
may still be prudent in patients with Anderson’s disease or
in those with unclear phenotypes.
In addition to a mutation in the SAR1B gene, patient
AD3 also has a polymorphism in the PCSK9 gene
(OMIM 607786), which encodes the Proprotein Conver-
tase Subtilisin/Kexin type 9. It is linked to autosomal
dominant hypercholesterolemia and is involved in choles-
terol homeostasis [36-39] and gain-of-function mutations
cause increased degradation of the LDL receptor and
result in high levels of LDL cholesterol [61,62]. Some
mutations of PCSK9 cause variable degrees of hypocho-
lesterolemia in homozygous or compound heterozygous
carriers [63,64]. However, these PCSK9 hypocholesterole-
mias appear to be clinically benign. The PCSK9 poly-
morphism found in patient AD3 was found to be present
at a higher frequency in a low LDL-C population than in
a normal population and to segregate with the “apoB-
negative” Familial Hypobetalipoproteinemia phenotype in
3 families [49]. This polymorphism could be an addi-
tional genetic hypocholesterolemic variation that might
account for the high variability in lipid levels of some
patients with AD. We did not find, in any of the three
patients, a mutation in exon 7 of the LDLR gene which
encodes the EGF A repeat domain of the LDL receptor
which is essential for PCSK9 binding [62]. A mutation in
this binding site could prevent the degradation of the
LDL receptor by PCSK9 and also could lead to hypocho-
lesterolemia due to an increase in LDL catabolism [65].
The variation in the PCSK9 gene is the second example
of a mutation in the SAR1B gene being accompanied by a
mutation/variation in another gene. In the cases of
CMRD-MSS (Marinesco-Sjogren Syndrome), there is, in
addition to a mutation in the SAR1B gene, a mutation in
the SIL1 gene [20]. In these patients, CMRD and MSS
are distinct diseases.
Although chylomicron retention disease or Anderson’s
disease has been shown to be attributable to variations
in the SAR1B gene, a full understanding of the relation-
ship between genotype and phenotype and the origins of
tissue-specific manifestations is lacking.
The SAR1B gene mutations in the three AD patients
d e s c r i b e dh e r ea r ep r e d i c t e dt ol e a dt os e v e r e l y
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amino acids, respectively, the first 27 or 47 of which
correspond to the amino-terminal sequence of the wild
type protein. These truncated proteins lack numerous
essential conserved residues that are involved in guanine
nucleotide binding, in GTP hydrolysis and for interact-
ing with guanine nucleotide exchange factors (GEF) and
GTPase-activating proteins (GAP). We expect that the
SAR1B proteins produced are non-functional in these
patients. The vast majority of SAR1B gene mutations in
AD/CMRD affect regions that are involved in nucleotide
binding and hydrolysis as well as other functions (see
Table and Figure as Additional files 1 and 2). A few
others affect primarily regions in proximity to the mem-
brane which would also be suspected to severely alter
the function of the protein [12,18,19,22,66].
Sarl plays at least two roles in the secretory pathway.
Sar1 is a significant participant in the coat protein com-
plex II (COPII), a multi-protein complex which is
responsible for the formation, at the endoplasmic reticu-
lum, of membrane vesicles involved in protein transport
(protein transport vesicles, PTVs) to the Golgi compart-
ment [27-30]. Sar1, a small GTPase, associates with the
smooth ER membrane via the action of Sec12, a GTP/
GDP exchange factor. After having bound GTP, Sar1
binds Sec23-Sec24 (the inner coat) to form a prebud-
ding complex. This complex, via Sec24 and perhaps
Sec23 and Sar1, as well, interacts with vesicle cargos.
Sec13-Sec31, which form the outer coat, are recruited
by the Sar1-Sec23-Sec24 complex, which is membrane
bound. The outer coat stimulates the GTPase-activating
protein Sec23 which activates Sar1 GTP hydrolysis
allowing depolymerisation of the coat and recycling of
its components. PTVs transport a wide range of soluble
and membrane bound cargo in a COPII dependent
manner.
In a novel paradigm, Sar1 plays a role in an intestinal
chylomicron-specific transport mechanism that employs
a pre-chylomicron transport vesicle (PCTV). However, in
this mechanism, it is L-FABP that initiates and organizes
the PCTV budding machinery [32] which is modified and
regulated, in part, by the phosphorylation of a currently
unidentified 9 kDa protein [67]. It is of interest in this
context that FABP gene disrupted mice exhibit a delayed
appearance of dietary triglycerides in the blood [68,69].
PCTVs, similarly to PTVs require ATP. In contrast to
PTVs, the PCTVs do not require GTP and the vesicle
size is markedly larger (200-500 nm for PCTVs as
opposed to 60-90 nm for PTVs). Further, the PCTV does
not require Sar1 to bud from the ER but rather employs
all the COPII proteins, and in particular Sec24C, for
docking and fusion with the cis-Golgi [31,33,34,70,71].
Prior binding of Sar1 to PCTVs is apparently necessary
for the binding of Sec24C [34]. Finally, VAMP7 is the v-
SNARE present on PCTVs, whereas Ykt6 and r22b are
the v-SNAREs on PTVs [33].
Given the important role of Sar1 in COPII assembly and
in the secretory pathway, it is remarkable that AD/CMRD
patients have a pathology which is limited primarily to the
intestine. Recent studies of cranio-lenticulo-sutural dyspla-
sia CLSD [28,72,73] and congenital dyserythropoietic ane-
mia type II, CDAII, [53] in humans and craniorachischisis
in mice [74] provide important insights. The mutation in
CLSD affects SEC23A, and the pathological effects are also
limited. There are two paralogues of Sec23 and it appears
that the second paralogue, SEC23B, can compensate for
the loss of activity of SEC23A. Manifestation of the disease
occurs, presumably, in tissues where there is not enough
SEC23B to compensate for the loss of the other paralogue.
However, in CDAII, in which a specific erythropoietic phe-
notype is observed, SEC23A can not compensate for the
paralogue, SEC23B, which is important in the cell cycle of
erythroid cells and their cytokinesis [53]. In contrast, in
craniorachischisis, Sec24b is affected but also with rather
limited effects (although severe). In this case, transport of
a specific cargo is strictly dependent on Sec24b indicating
that cargo specificity has evolved among the four Sec24
paralogues.
The question arises as to whether in AD/CMRD and
for the case of SAR1, for which there are also two human
paralogues, the disease becomes manifest only in tissues
in which there is insufficient amounts of the second para-
l o g u et oc o m p e n s a t ef o rt h el o s so fa c t i v i t yo ft h ef i r s t
paralogue or whether a specific cargo (chylomicrons) is
strictly dependent on a specific paralogue(s) of the secre-
tion machinery. Both the SAR1A and SAR1B genes are
expressed in the intestine [18,50,51]. Our results show
that the expression of the SAR1B gene in the duodenal
biopsies from the patient AD3 was markedly decreased
as compared to healthy individuals. In contrast, the
expression of the normal SAR1A gene was significantly
increased in AD3. The increased expression of the
SAR1A gene and, presumably, of its encoded protein,
SAR1A, does not appear to be sufficient to compensate
for the defect in SAR1B. This is consistent with a Sar1
paralogue-specific and cargo-specific transport of
chylomicrons.
In AD/CMRD, Sar1 paralogue- and cargo-specific trans-
port could explain the rather modest and tissue specific
manifestations of the disease. If, in enterocytes, the SAR1B
paralogue is used specifically in PCTV vesicles, for the
transport of chylomicrons, and if the SAR1A paralogue is
used in PTVs, for the transport of small soluble and mem-
brane bound proteins, then mutations in SAR1B would be
expected to affect primarily or only chylomicron transport.
Indeed, it has been shown that SAR1B has a weaker affi-
nity for SEC13-SEC31A which could lead to a less con-
strained structure [73]. This less constrained structure
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could transport large cargos such as chylomicrons) as
compared to those assembled with SAR1A which has a
stronger affinity for SEC13-31A [28,75].
It has been proposed, in fact, that mutated SAR1B
protein leads to an absence of chylomicronemia in AD
because the PCTVs that are produced in the absence of
Sar1 do not fuse with the Golgi and are retained in the
cytosol [34]. In contrast, in a COPII-GTP-dependent
model and by analogy to the disease CLSD in humans, a
mutated Sar1 protein might be expected to lead to the
accumulation of tubular extensions, devoid of a coat,
projecting from distended peripheral ER compartments
as a consequence of defective budding [28,72,73]. Elec-
tron micrographs of appropriate resolution might be
able to distinguish between these two possibilities but,
to the present, the heavily lipid-laden nature of the
enterocytes obtained from patients with AD, even in the
fasted state, has precluded this.
With respect to the liver, the lack of hepatic manifesta-
tions in most cases of AD, (hepatic steatosis has been
reported in only 4 patients [8,12]) could be explained by
differences in intestinal and hepatic trafficking pathways
which might also use different COPII paralogues and, in
particular, SAR1A for the secretion of apoB100-containing
lipoproteins. It has been proposed that a smaller VLDL-
specific transport vesicle, the VTV, requires Sar1 (it is
n o tc l e a ra st ot h ei s o f o r mi n v o l v e d )t oe x i tf r o mt h e
ER and also involves the ER-to Golgi vSNARE, rSec22b,
which is not present in the intestinal PCTV [71,76,77].
Gusarova et al. also have reported that the exit of
apoB100 from ER membranes in the rat liver requires
COPII proteins but that the size of the lipoprotein
entering the vesicle is small with further lipidation
occurring downstream from COPII dependent events
[78]. Interestingly, patients with CLSD (SEC23A muta-
tion) are not reported to have decreased cholesterol
levels, malabsorption or hepatic steatosis which could
point to the importance of the different COPII coat
paralogues in the PTV, PCTV and VTV transport sys-
tems. Differences in the protein composition of the
PTV, PCTV and VTV vesicles could also account for
the differences in their cargo proteins. Taken together,
the data from AD/CMRD patients suggest that specific
sequences of SAR1B are essential for the intracellular
processing of intestinal chylomicrons and are less
important for hepatic VLDL secretion.
A final remark concerns the amount and the localiza-
tion of the Sar1 protein observed by immunostaining.
Sar1 immunostaining was found to localize heteroge-
neously in the villi and in the enterocytes of both healthy
individuals and patients. Immunostaining was frequently
observed on only one side of the villus and was concen-
trated in the apical region of the enterocytes. This pattern
has been described previously for lipid droplets in AD, in
CRD- Marinesco-Sjoren syndrome [14,15] as well as for
proteins involved in the chylomicron secretory pathway,
including hepatic FABP [79] which is purported to be
involved in the budding step of the PCTV [32]. This pat-
tern is reminiscent of the mosaicism observed for other
proteins [80-82]. Whether this distribution is related to
several populations of enterocytes arising from different
stem cells [83] or to some other physiological mechanism
is not known. Further, although the I and L-FABP genes
have been reported as not being responsible for AD [14],
L-FABP has been shown to be present but in reduced
amounts in the enterocytes of AD patients as assessed by
immunohistochemical analysis [79]. The reason for this
a n di t sp o s s i b l er o l ei nt h ep a t h o l o g yo fA Dr e m a i n s
unexplained.
The complexity of the secretory machinery and the
numerous combinations of the different paralogues sug-
gests that phenotypes similar to AD/CMRD could arise
from other mutations in either tissue specific or common
elements belonging to the intestinal and hepatic apoB-
containing lipoprotein secretory pathways. We have, in
fact, now found four families with 6 affected individuals
that exhibit the AD/CMRD phenotype in which the
SAR1B gene is normal (unpublished results). We are cur-
rently in the process of defining the genetic defect in these
families.
Additional material
Additional file 1: List of mutations in the SAR1B gene reported in
AD/CMRD patients. List of individuals for whom a mutation in the
SAR1B gene has been described along with the predicted amino acid
change, predicted effect on the protein and references.
Additional file 2: SAR1B structural and functional domains. The
sequence and secondary structure of human SAR1B and the functional
roles that have been attributed to regions of the protein (based upon
the data in the references cited) are shown along with the positions of
the mutations identified in cases of Anderson’s Disease/Chylomicron
Retention Disease.
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